All articles tagged with #pfizer
Vaxcyte reported positive phase 3 results for its 31-valent pneumococcal vaccine, VAX-31, demonstrating non-inferiority against Pfizer and Merck competitors. The stock surged 57% in pre-market trading, reaching $88.50, as the company prepares for an FDA approval application in early 2028.
Updated COVID-19 vaccines targeting the XFG variant are now available in the US, with the FDA approving four formulations in late August. While medical groups broadly recommend vaccination to prevent severe illness, public uptake remains mixed due to lingering skepticism. A new JAMA review confirms that updated shots significantly reduce hospitalizations and deaths, particularly for older adults, though no specific data exists yet for the 2026-2027 formula.
Exclusive Washington Post documents show the Trump administration’s confidential drug-pricing deals with Pfizer and Eli Lilly included inducements to raise prices overseas, tariff protections, and broad confidentiality clauses, with redactions prompting scrutiny and a challenge by Public Citizen over the terms’ value to patients.
The FDA has approved four updated COVID-19 vaccines from Pfizer (Comirnaty), Moderna (Spikevax and mNexspike) and Novavax (Nuvaxovid) that target the Omicron XFG variant; Moderna’s mNexspike uses a lower 10 µg dose. Vaccines are being shipped to clinics and pharmacies; the guidance is to vaccinate unvaccinated or high‑risk individuals (65+ or with certain conditions). For timing, aim to receive the shot around October to cover the winter season, bearing in mind protection wanes after about six months. If recommended, the vaccine is usually free with insurance, while uninsured Utahns can use the Utah Vaccines For Adults program to obtain vaccines cheaply.
Lyme disease cases are rising as ticks expand due to climate change, and there are currently no licensed vaccines for people, though several are advancing. Pfizer/Valneva's four-dose PF-07307405 vaccine showed over 70% efficacy in a large phase 3 trial; Moderna is testing two Lyme vaccines in phase 2; Yale is exploring a tick-saliva–targeting approach; and Tonix's TNX-4800 antibody injections are in early trials, with Tarsus pursuing an oral pill. In dogs, tick protection is common, while preventive strategies for humans emphasize avoiding tall grass, protective clothing, and thorough tick checks. A prior human vaccine, LYMErix, disappeared in 2002 due to safety concerns and low demand.
The FDA has approved updated COVID-19 vaccines from Moderna, Pfizer, and Novavax for the 2026–2027 season, all targeting the XFG variant. Distribution will begin soon, with eligibility continuing to favor older adults and people with high-risk conditions, while vaccination remains available to others. The vaccines use the flexible mRNA platform for rapid redesign and aim to prevent severe illness, hospitalization, and death, with benefits varying by individual risk.
Pfizer beat expectations for Q2 earnings and revenue and raised its full-year guidance thanks to strength in non-Covid drugs, but Paxlovid revenue plunged about 95% and Comirnaty declined around 34%, prompting cost-cutting moves. BioNTech missed revenue targets, and Pfizer’s stock edged lower on the news.
A Danish Medicines Agency study using about 3 million women's health data over 25 years found Depo-Provera and five other hormonal birth control drugs are linked to a small, temporary increase in risk for meningioma, a rare brain tumor. The risk is higher during use and largely fades within five years after stopping; the absolute risk remains very low.
Nike announced that David M. Denton will join as Executive Vice President and Chief Financial Officer, effective August 17, succeeding Matthew Friend who will step down but stay through September 4 to ensure a smooth transition. Denton, currently CFO of Pfizer since 2022, has more than 30 years of finance leadership at companies including Lowe’s and CVS Health and prior board experience. Nike also updated on fourth-quarter/fiscal-2026 results (June 30); the report will include a one-time tariff-refund benefit and is expected to be broadly in line with prior guidance absent that benefit.
Pfizer’s first new ADC after acquiring Seagen failed to meet its primary endpoint in a phase 3 nonsquamous NSCLC trial, showing no significant overall survival advantage vs docetaxel. The company cites a stronger signal in a patient subgroup with one prior therapy and notes ongoing phase 3 studies combining sigvotatug vedotin with pembrolizumab in first-line NSCLC, sustaining optimism for the program despite the setback.
Mid-stage data from Pfizer’s obesity drug berobenatide (from Metsera) suggest dosing it monthly after an initial weekly period can sustain weight loss through 28 weeks, with up to 12.1% loss in patients who stayed on treatment, though the monthly pace lags Lilly’s Zepbound and competitive clarity remains uncertain.
Pfizer presented midstage results for berobenatide, a monthly GLP-1 obesity drug acquired with Metsera for $10 billion, showing a side-effect profile similar to Novo Nordisk’s Wegovy (average nausea ~38%, vomiting ~23%). The long half-life makes monthly dosing front-loaded, and researchers plan a slower dose ramp in late-stage trials. Weight loss reached up to 12.3% in non-diabetics; analysts expect 20–25% vomiting and see monthly dosing as a potential differentiator from weekly rivals like Wegovy and Lilly’s Zepbound.
Chai Discovery announced a license with Pfizer to deploy its frontier AI platform, including the Chai-3 model and a Pfizer-custom model, within Pfizer’s drug discovery engine to accelerate biomolecule design and target hard-to-reach areas. Pfizer will gain early access to Chai-3, which advances antibody design and generalization, alongside a tailored model leveraging Pfizer’s data. The deal highlights growing use of AI in pharma to shorten discovery timelines that traditionally span months to weeks.
Pfizer and Innovent announced a broad collaboration worth up to $10 billion to develop 12 cancer medicines, starting with a $650 million upfront and up to $9.85 billion in milestones. Pfizer will gain exclusive global licenses for four programs, ex-China rights to four, and co-develop four with Innovent, while Innovent handles eight programs through phase 1. The partners will co-commercialize jointly owned assets in the U.S. and Europe, illustrating how Western pharma is leveraging China’s rapid early development to boost productivity and global reach.
Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.